Literature DB >> 22568405

Long-term outcomes for adult craniopharyngioma following radiation therapy.

Laurence Masson-Cote1, Giuseppina Laura Masucci, Eshetu G Atenafu, Barbara-Ann Millar, Michael Cusimano, Sidney Croul, Warren Mason, Normand J Laperriere, Arjun Sahgal.   

Abstract

BACKGROUND: We report long-term outcomes in adult patients with craniopharyngioma following surgery and radiation therapy (RT).
MATERIAL AND METHODS: Fifty-three patients treated with RT (median, 50 Gy in 25 fractions) between 1980 and 2009 with pathologically confirmed craniopharyngioma were reviewed (53% solid and 47% cystic/solid). The median age was 53 years (range, 22-76), 53% were female, 83% were sub-totally resected, 6% were gross totally resected and 11% had a biopsy and/or cyst aspiration alone. RT was delivered adjuvantly in 53% of patients as opposed to salvage intent upon progression.
RESULTS: Median follow-up was seven years (86 months, range, 8-259). The 5- and 10-year progression-free survival (PFS) rates were 85% and 69%, overall survival (OS) rates were 76% and 70%, and cause-specific survival (CSS) rates were both 88%, respectively. Both univariable and multivariable analysis identified age (<53 or ≥53) as a prognostic factor for OS (p =0.0003) and CSS (p =0.05). PFS was observed to be worse in patients with >2 surgeries prior to RT (p =0.01). Neither the intent of radiation or tumor type (cystic vs. solid/cystic) were prognostic or predictive. New endocrinopathies and visual dysfunction were observed in 53% and 17% of patients post-surgery, and in 11% and 6% post-RT, respectively.
CONCLUSION: We report long-term favorable PFS, CSS and OS for craniopharyngioma post-RT. We observe age as a significant prognostic factor, however, timing of radiation was not.

Entities:  

Mesh:

Year:  2012        PMID: 22568405     DOI: 10.3109/0284186X.2012.685525

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  7 in total

Review 1.  Excess mortality after craniopharyngioma treatment: are we making progress?

Authors:  Nidan Qiao
Journal:  Endocrine       Date:  2018-12-19       Impact factor: 3.633

2.  Risk factors for and predictive nomogram of overall survival in adult patients with craniopharyngiomas: A SEER population-based study.

Authors:  Yong Wu; Bo Xu; Sheng Hu; Bi-Bo Shao
Journal:  Medicine (Baltimore)       Date:  2022-07-01       Impact factor: 1.817

3.  Clinical outcomes following proton therapy for adult craniopharyngioma: a single-institution cohort study.

Authors:  Michael S Rutenberg; Ronny L Rotondo; Dinesh Rao; Adam L Holtzman; Daniel J Indelicato; Soon Huh; Christopher G Morris; William M Mendenhall
Journal:  J Neurooncol       Date:  2020-02-21       Impact factor: 4.130

4.  Disease Control after Radiotherapy for Adult Craniopharyngioma: Clinical Outcomes from a Large Single-Institution Series.

Authors:  Michael S Rutenberg; Adam L Holtzman; Daniel J Indelicato; Soon Huh; Dinesh Rao; Peter J Fiester; Christopher G Morris; Daryoush Tavanaiepour; Robert J Amdur
Journal:  J Neurooncol       Date:  2022-03-12       Impact factor: 4.130

5.  Long term results after fractionated stereotactic radiotherapy (FSRT) in patients with craniopharyngioma: maximal tumor control with minimal side effects.

Authors:  Semi B Harrabi; Sebastian Adeberg; Thomas Welzel; Stefan Rieken; Daniel Habermehl; Jürgen Debus; Stephanie E Combs
Journal:  Radiat Oncol       Date:  2014-09-16       Impact factor: 3.481

6.  Non-coplanar volumetric-modulated arc therapy (VMAT) for craniopharyngiomas reduces radiation doses to the bilateral hippocampus: a planning study comparing dynamic conformal arc therapy, coplanar VMAT, and non-coplanar VMAT.

Authors:  Megumi Uto; Takashi Mizowaki; Kengo Ogura; Masahiro Hiraoka
Journal:  Radiat Oncol       Date:  2016-06-23       Impact factor: 3.481

7.  Genetic and immune profiling for potential therapeutic targets in adult human craniopharyngioma.

Authors:  Cynthia Kassab; Daniel Zamler; Carlos Kamiya-Matsuoka; Zoran Gatalica; Joanne Xiu; David Spetzler; Amy B Heimberger
Journal:  Clin Oncol Res       Date:  2019-06-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.